Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Anna-Lena Volckmar
Affiliation
Institut fur Pathologie, Universitatsklinikum Heidelberg
ORCID
Career Start Year
2010
Papers
83
H Index
26
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
36635225
First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma.
J Pathol Clin Res
2023
37792098
[Regulation (EU) 2017/746 (IVDR): practical implementation of annex I in pathology].
Pathologie (Heidelb)
2023
37586177
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
Lung Cancer
2023
34331337
Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.
Genes Chromosomes Cancer
2022
35871236
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.
Br J Cancer
2022
35925306
[Structure and content of the EU-IVDR : Current status and implications for pathology].
Pathologie (Heidelb)
2022
35879369
Evidence for correlations between BMI-associated SNPs and circRNAs.
Sci Rep
2022
33971666
Knowledge bases and software support for variant interpretation in precision oncology.
Brief Bioinform
2021
33686791
KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.
Genes Chromosomes Cancer
2021
33715240
RREB1-MKL2 fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site?
Genes Chromosomes Cancer
2021
33667718
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
Lung Cancer
2021
34408792
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.
Ther Adv Med Oncol
2021
34605937
Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie.
Pathologe
2021
33938987
[Variant interpretation in molecular pathology and oncology : An introduction].
Pathologe
2021
34073477
Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival.
Cancers (Basel)
2021
34125166
Knowledge bases and software support for variant interpretation in precision oncology.
Brief Bioinform
2021
34012783
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.
Transl Lung Cancer Res
2021
33959513
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer.
Front Oncol
2021
33976623
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.
Case Rep Oncol
2021
34164264
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.
Transl Lung Cancer Res
2021
32212351
Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.
Genes Chromosomes Cancer
2020
31970771
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Int J Cancer
2020
31925805
Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
Hepatology
2020
33161228
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
EBioMedicine
2020
32871455
Risk stratification of EGFR<sup>+</sup> lung cancer diagnosed with panel-based next-generation sequencing.
Lung Cancer
2020
32280037
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.
Urol Oncol
2020
30306707
Gain-of-function variants in the melanocortin 4 receptor gene confer susceptibility to binge eating disorder in subjects with obesity: a systematic review and meta-analysis.
Obes Rev
2019
31753813
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1-ALK</i>-rearranged lung cancer.
Cold Spring Harb Mol Case Stud
2019
30216696
Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma.
Proteomics Clin Appl
2019
30238975
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
Int J Cancer
2019
30230086
Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.
Genes Chromosomes Cancer
2019
31491926
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.
Cancers (Basel)
2019
31349062
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
J Thorac Oncol
2019
31549213
The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Cancer Immunol Immunother
2019
31008532
Variant classification in precision oncology.
Int J Cancer
2019
31089797
[From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?]
Pathologe
2019
30963573
Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.
Int J Cancer
2019
30653256
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Int J Cancer
2019
30669647
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.
Cancers (Basel)
2019
30446996
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
Int J Cancer
2019
27367046
High-throughput DNA methylation analysis in anorexia nervosa confirms TNXB hypermethylation.
World J Biol Psychiatry
2018
35135162
Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.
JCO Precis Oncol
2018
30134862
Relevance of polymorphisms in MC4R and BDNF in short normal stature.
BMC Pediatr
2018
30348504
Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases.
Pathology
2018
30454709
Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.
Eur J Cancer
2018
30505715
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.
Transl Lung Cancer Res
2018
29631267
The Effect of SH2B1 Variants on Expression of Leptin- and Insulin-Induced Pathways in Murine Hypothalamus.
Obes Facts
2018
29205637
A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Genes Chromosomes Cancer
2018
29269125
Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.
Pathology
2018
29044880
Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.
Genes Chromosomes Cancer
2018
1 - 50 of 83
Column Actions
Search
Recommended Authors
Nayoung K D Kim
Samsung Genome Institute, Samsung Medical Center
Career Start Year
2013
Number of shared co-authors
0
Kuan-Lin Huang
Icahn School of Medicine at Mount Sinai
Career Start Year
2013
Number of shared co-authors
0
John D Overton
Regeneron Pharmaceuticals
Career Start Year
2008
Number of shared co-authors
1
Hui Zhao
College of Life Sciences, University of Chinese Academy of Sciences
Career Start Year
2007
Number of shared co-authors
0
Sigve Nakken
University of Oslo
Career Start Year
2007
Number of shared co-authors
6
Katia Nones
QIMR Berghofer Medical Research Institute
Career Start Year
2006
Number of shared co-authors
0
Mark J Cowley
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year
2006
Number of shared co-authors
2
Danielle M Greenawalt
Bristol-Myers Squibb Co.
Career Start Year
2006
Number of shared co-authors
7
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year
2006
Number of shared co-authors
6
Alison Meynert
Institute of Genetics and Cancer, University of Edinburgh
Career Start Year
2006
Number of shared co-authors
0
Ann-Marie Patch
QIMR Berghofer Medical Research Institute
Career Start Year
2005
Number of shared co-authors
6
Robert C Onofrio
The Broad Institute of Harvard and MIT
Career Start Year
2005
Number of shared co-authors
4
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year
2005
Number of shared co-authors
1
Laurie Burdett
National Cancer Institute, Frederick National Laboratory for Cancer Research
Career Start Year
2005
Number of shared co-authors
0
Abul Kalam Azad
University of Dhaka
Career Start Year
2004
Number of shared co-authors
0
Rebecca Nagy
Guardant Health Inc.
Career Start Year
2004
Number of shared co-authors
4
Olivier Harismendy
University of California
Career Start Year
2003
Number of shared co-authors
0
Obi L Griffith
Washington University
Career Start Year
2003
Number of shared co-authors
5
Stacey Gabriel
Broad Institute of MIT and Harvard
Career Start Year
2001
Number of shared co-authors
16
Vladimir Makarov
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
Career Start Year
2001
Number of shared co-authors
5
Eric W Klee
Mayo Clinic College of Medicine and Science
Career Start Year
2001
Number of shared co-authors
2
Yan W Asmann
Mayo Clinic
Career Start Year
2000
Number of shared co-authors
1
Hugues Sicotte
Mayo Clinic
Career Start Year
1999
Number of shared co-authors
2
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Career Start Year
1999
Number of shared co-authors
1
Dirce Maria Carraro
AC Camargo Cancer Center
Career Start Year
1998
Number of shared co-authors
0
Carrie Sougnez
The Broad Institute of Harvard and MIT
Career Start Year
1998
Number of shared co-authors
2
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year
1997
Number of shared co-authors
0
John V Pearson
QIMR Berghofer Medical Research Institute
Career Start Year
1996
Number of shared co-authors
6
Curtis Gumbs
The University of Texas MD Anderson Cancer Center
Career Start Year
1995
Number of shared co-authors
0
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Career Start Year
1986
Number of shared co-authors
3
row(s) 1 - 30 of 30
Collaborators
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers
54
Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers
43
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Co-authored papers
38
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Co-authored papers
29
Anke Hinney
University Hospital Essen, University of Duisburg-Essen
Co-authored papers
28
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Co-authored papers
22
Johannes Hebebrand
LVR-Universitatsklinikum Essen, Kliniken und Institut der Universitat Duisburg-Essen
Co-authored papers
22
Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
Co-authored papers
22
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers
20
Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
Co-authored papers
19
Holger S??ltmann
German Cancer Research Center (DKFZ)
Co-authored papers
13
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers
12
Harald Grallert
Co-authored papers
7
H-Erich Wichmann
Co-authored papers
6
Ivo Buchhalter
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Co-authored papers
6
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers
5
Thomas Illig
Co-authored papers
5
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers
5
Heike Biebermann
Co-authored papers
5
Esther Herpel
Institute of Pathology, University Hospital Heidelberg
Co-authored papers
5
Huriye Seker-Cin
Institute of Pathology, Heidelberg University Hospital
Co-authored papers
4
Martin Klingenspor
Technical University of Munich
Co-authored papers
4
Thomas Longerich
Institute of Pathology, University Hospital Heidelberg
Co-authored papers
4
Stefan Schreiber
Co-authored papers
4
Markus M N??then
Institute of Human Genetics, University Hospital Bonn
Co-authored papers
3
Karl-Heinz Jöckel
Co-authored papers
3
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers
3
Andreas Reif
University Hospital Frankfurt am Main
Co-authored papers
3
Thomas W Winkler
Co-authored papers
3
Matthias Schlesner
University of Augsburg
Co-authored papers
3
1 - 30